Cystadenoma

A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)

Also Known As:

Networked: 469 relevant articles (9 outcomes, 42 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Hemangioma (Angioma)
3.	Tuberous Sclerosis (Bourneville's Disease)
4.	Ascites
5.	Carcinoma (Carcinomatosis)

Experts

1.	Xie, Dan: 7 articles (10/2019 - 01/2005)
2.	Kwiatkowski, David J: 6 articles (03/2015 - 10/2003)
3.	Yang, Guo-Fen: 5 articles (10/2019 - 02/2009)
4.	Yu, Yinhua: 5 articles (10/2013 - 10/2004)
5.	Zeng, Yi-Xin: 5 articles (01/2013 - 01/2005)
6.	He, Wei-Peng: 4 articles (11/2019 - 04/2010)
7.	Liu, Jinsong: 4 articles (01/2014 - 10/2004)
8.	Guan, Xin-Yuan: 4 articles (06/2010 - 01/2005)
9.	Dubeau, Louis: 3 articles (12/2018 - 09/2003)
10.	Zheng, W: 3 articles (12/2016 - 01/2000)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Cystadenoma:

1.	CateninsIBA 04/28/2021 - "Remarkably, in vivo functional analyses of β-catenin in the Pdx-1-Cre LKB1L/L β-cateninL/L mouse model compared to LKB1 loss-driven cystadenoma demonstrate that the loss of β-catenin impairs cystadenoma development in the pancreas of Pdx-1Cre LKB1L/L mice and dramatically restores the normal development and functions of the pancreas. " 04/28/2021 - "Inhibition of β-Catenin Activity Abolishes LKB1 Loss-Driven Pancreatic Cystadenoma in Mice." 04/28/2021 - "This study further determined the in vivo and in vitro therapeutic efficacy of the β-catenin inhibitor FH535 in suppressing LKB1 loss-driven cystadenoma and reducing PC progression that delineates the potential roles of Wnt/β-catenin signaling in PC harboring LKB1 deficiency."
2.	FH535IBA 04/28/2021 - "This study further determined the in vivo and in vitro therapeutic efficacy of the β-catenin inhibitor FH535 in suppressing LKB1 loss-driven cystadenoma and reducing PC progression that delineates the potential roles of Wnt/β-catenin signaling in PC harboring LKB1 deficiency."
3.	DNA (Deoxyribonucleic Acid)IBA 06/18/2007 - "We reported earlier that such ovarian cystadenoma cell cultures undergo severe changes in DNA ploidy as they approach crisis and that such changes are an important determinant of crisis independent of telomere attrition. " 01/01/2004 - "In 8 patients with benign and/or borderline ovarian cystadenoma, a complete sequencing of coding fragments of the BRCA2 gene from the peripheral blood DNA was performed. " 01/01/2003 - "The DNA index may be a useful independent factor for predicting the diagnosis of ovarian cystadenoma." 01/01/2003 - "[Prognostic significance of cellular DNA content and AgNOR count in ovarian cystadenoma]." 12/01/1993 - "DNA index and cell cycle distribution might be valuable in reflecting the biological behavior of deteriorating ovarian cystadenoma. "
4.	Contrast MediaIBA 02/01/2012 - "Diagnosis of a biliary cystadenoma demonstrating communication with the biliary system by MRI using a hepatocyte-specific contrast agent." 01/01/2011 - "Biliary cystadenoma with bile duct communication depicted on liver-specific contrast agent-enhanced MRI in a child." 01/01/2011 - "We present a 9-year-old boy with biliary cystadenoma, diagnosed by MRI using a new liver-specific contrast agent (gadoxetic acid) that is eliminated by the biliary system. " 07/01/2000 - "Because the mucin secreted by biliary cystadenomas and cystadenocarcinomas causes filling defects and partial obstruction of contrast material at ERCP, MRCP is potentially more accurate in demonstrating the extent of these tumors. " 12/31/2009 - "hepatocellular carcinoma or liver metastasis) or infectious diseases; (3) For differentiation diagnosis between biliary cystadenoma and biliary cystadenocarcinoma; (4) To detect malignant change in Caroli's disease; (5) To depict the extent of Klatskin's tumor with greater clarity; (6) To make a distinction between gallbladder cholesterol polyp, adenoma and polypoid cancer; (7) To make a distinction between chronic cholecystitis with thickened wall and gallbladder cancer; (8) For differentiation diagnosis between motionless sludge and gallbladder cancer; (9) For differentiation diagnosis between common bile duct cancer and sludge or stone without acoustic shadowing; and (10) In patients who are suspected of having a drop of their percutaneous transhepatic cholangiodrainage tube, US contrast agent can be administered to through the tube detect the site of the tube."
5.	SilverIBA 01/01/2003 - "It has been showed that cellular DNA content and silver-staining nucleolar organizer region (AgNOR) count were significantly associated with the prognosis of some tumors; however, it is not yet clear whether these two parameters be helpful in predicting the prognosis of ovarian cystadenoma. "
6.	Atorvastatin (Lipitor)FDA Link 07/01/2009 - "Following atorvastatin treatment, no significant reduction in tumor size, morphology, or phosphorylated S6 levels was observed for either ENU-associated renal cystadenoma or spontaneous liver hemangioma as compared with the untreated groups. " 07/01/2009 - "We tested atorvastatin as a therapy for (a) ethylnitrosourea (ENU)-enhanced renal cystadenoma and (b) spontaneous liver hemangioma in 129Sv/Jae Tsc2(+/-) mice. "
7.	Imatinib Mesylate (Gleevec)FDA Link 01/01/2023 - "The efficacy of imatinib therapy was validated against spontaneously developing renal cystadenomas in tuberous sclerosis Tsc2+/- mouse models (C57BL/6J mice; N = 6; 400 mg/kg/d; oral gavage) compared with Tsc2+/- mice treated with PBS (C57BL/6J mice; N = 6). "
8.	gadolinium ethoxybenzyl DTPAFDA Link 01/01/2011 - "We present a 9-year-old boy with biliary cystadenoma, diagnosed by MRI using a new liver-specific contrast agent (gadoxetic acid) that is eliminated by the biliary system. "
9.	4-O-carboxymethylascochlorinIBA 01/01/2010 - "It is safe and effective to perform enucleation for well-selected benign pancreatic cystadenomas even if the tumor size is as large as 6 cm, and the endocrine or exocrine function of the pancreas is maintained as much as possible."
10.	Proteins (Proteins, Gene)FDA Link 01/01/2021 - "The present study analyzed the correlations among the expressions of these three proteins and their relationships with the clinicopathological characteristics and survival of patients with SOC. The expressions of NCAPH, AGGF1, and FOXC2 were detected by the immunohistochemical examination of 153 SOC tissue samples and 30 serous ovarian cystadenoma tissue samples. " 12/01/2014 - "To initiate the study we determined expression of this protein in normal and cancerous ovarian tissues, cystadenomas, metastatic lesions, and ovarian cancer cell lines. " 02/01/2006 - "In this study, we analyzed the expression patterns of the p53 protein in 22 cases of GBC, 17 cases of precursor lesions (16 gallbladder adenomas and 1 cystadenoma), and 15 cases of normal epithelia using immunohistochemical analysis. " 12/01/2018 - "Thus, HCMV proteins are detected at different levels in ovarian tumors and benign cystadenomas. " 01/01/2010 - "On immunohistochemical examinations it was found a significantly higher immunoexpression of both examined proteins in invasive serous ovarian cancers than in cystadenomas. "

Therapies and Procedures

1.	Therapeutics 06/21/2006 - "The differential diagnosis of the large cystic tumors which occupy the right hemiabdomen must include the biliary cystadenoma; the complete resection of the tumor with safety margins avoids local recurrence, and therefore represents the optimal therapy because of the malignant potential of the disease. " 05/01/2005 - "Cystadenomas are often incorrectly diagnosed as simple cysts, which results in inadequate therapy. " 01/01/2001 - "The optimal therapy for mucinous neoplasms of the pancreas is surgical resection because these tumours are either premalignant (cystadenoma) or malignant. " 01/01/2001 - "Cystadenoma of the liver without mesenchymal stroma in a female following hormonal therapy for acne." 05/01/2011 - "Therapy is fundamentally surgical: appendectomy is curative for simple AM, for AM with epithelial hyperplasia and for cystadenoma with intact appendiceal base; cecum resection is indicated for cystadenoma with larger base of implantation; right hemicolectomy has been the elective treatment in case of cystadenocarcinoma for several years although Gonzalez-Moreno and Sugarbaker have recently demonstrated its validity as definitive treatment only if it is performed in order to obtain complete cytoreduction, if there is lymph node involvement, or if histopathological examination indicates non-mucinous type. "
2.	Hepatectomy 04/21/2009 - "Left hepatectomy was performed and the patient was symptom-free during a 6-mo follow-up period, suggesting that imaging examination is the major diagnostic method of hepatobiliary cystadenoma, and operation is its best treatment modality." 11/01/2016 - "CENTRAL HEPATECTOMY FOR BILIARY CYSTADENOMA: PARENCHYMA-SPARING APPROACH FOR BENIGN LESIONS." 03/01/2013 - "All patients with hepatobiliary cystadenoma were treated by partial hepatectomy. " 07/01/2011 - "Ruptured biliary cystadenoma managed by angiographic embolization and interval partial hepatectomy." 02/01/1979 - "The authors describe one case of cystadenoma of the bile ducts removed by left hemi-hepatectomy. "
3.	Pancreaticoduodenectomy 12/29/1950 - "[Cystadenoma of the head of the pancreas cured by duodenopancreatectomy]." 04/13/2021 - "The preoperative diagnosis was pancreatic head cystadenoma, and laparotomic pancreaticoduodenectomy was initiated successfully. " 03/01/2008 - "The histopathological findings of the operative specimen (cephalic pancreatoduodenectomy) revealed a large serous multilocular cystadenoma. " 02/01/1998 - "A pancreaticoduodenectomy was performed for presumed cystadenoma. " 01/15/2021 - "Pancreaticoduodenectomy was performed, and final pathology demonstrated three separate neoplasms: serous cystadenoma, intraductal papillary mucinous neoplasm, and neuroendocrine tumor. "
4.	Surgical Portacaval Shunt (Portacaval Anastomosis) 04/01/1984 - "Location of the outflow block was suprahepatic (vena cava or major hepatic veins) in 13 patients and intrahepatic in 4. In five patients, a side-to-side portacaval shunt was effective in dissipating ascites with restoration to a normal lifestyle, as were transatrial fracture of a caval web (one patient) and resection of a huge cystadenoma of the liver (one patient). "
5.	Laparotomy 12/14/2021 - "We report a rare case of ruptured biliary cystadenoma in a pregnant woman diagnosed at emergency laparotomy. " 09/08/2009 - "Laparotomy confirmed the contrast enhanced computed tomography findings and histology revealed an intrahepatic mucinous biliary cystadenoma. " 11/07/2006 - "Emergency laparotomy for misdiagnosed biliary cystadenoma originating from caudate lobe." 08/01/2005 - "Cystadenoma and laparoscopic surgery for hepatic cystic disease: a need for laparotomy?" 08/01/1988 - "At laparotomy, a large cystic mass was resected from the left hepatic lobe, and diagnosed as biliary cystadenoma. "